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BioﬂuidsRaman spectroscopy is an optical technique based on inelastic scattering of light by vibrating molecules and can
provide chemicalﬁngerprints of cells, tissues or bioﬂuids. The high chemical speciﬁcity,minimal or lack of sample
preparation and the ability to use advanced optical technologies in the visible or near-infrared spectral range
(lasers, microscopes, ﬁbre-optics) have recently led to an increase in medical diagnostic applications of Raman
spectroscopy. The key hypothesis underpinning this ﬁeld is that molecular changes in cells, tissues or bioﬂuids,
that are either the cause or the effect of diseases, can be detected and quantiﬁed by Raman spectroscopy. Further-
more, multivariate calibration and classiﬁcation models based on Raman spectra can be developed on large
“training” datasets and used subsequently on samples from new patients to obtain quantitative and objective
diagnosis. Historically, spontaneous Raman spectroscopy has been known as a low signal technique requiring
relatively long acquisition times. Nevertheless, new strategies have been developed recently to overcome
these issues: non-linear optical effects and metallic nanoparticles can be used to enhance the Raman signals,
optimised ﬁbre-optic Raman probes can be used for real-time in-vivo single-point measurements, while multi-
modal integration with other optical techniques can guide the Raman measurements to increase the acquisition
speed and spatial accuracy of diagnosis. These recent efforts have advanced Raman spectroscopy to the point
where the diagnostic accuracy and speed are compatible with clinical use. This paper reviews the main Raman
spectroscopy techniques used in medical diagnostics and provides an overview of various applications.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Raman spectroscopy is a powerful analytical technique that can
measure the chemical composition of complex biological samples,
such as bioﬂuids, cells and tissues. A Raman spectrum represents a mo-
lecular ﬁngerprint of the sample and provides quantitative information
regarding its chemicalmakeup. Biochemical changes in cells and tissues,
that may either be caused or are the cause of a disease, can lead to
signiﬁcant changes in the Raman spectra. The potential of Raman
spectroscopy arises from its ability to detect such biochemical changes
at amolecular level, and therefore, can be used for diagnostics, prognos-
tics or as a tool for evaluating new therapies.
Raman spectroscopy has several features that are advantageous for
medical diagnostics. It has high chemical speciﬁcity and molecular in-
formation can be obtained without requiring staining or labelling.
Changes in the molecular composition of biological samples as
measured by Raman spectroscopy can be used to build multivariate
calibration and classiﬁcation models, which allow quantitative and
objective diagnosis for independent patients. Raman spectroscopy
relies on scattering of light by molecules and information regarding
the vibrational modes of the molecules can be obtained using visible
or near-infrared lasers. Thus, Raman spectroscopy can take advantage
of the advanced optical microscopy technologies, optical ﬁbres,
miniaturised lasers and other photonic devices, to improve diagnostic
performance and speed. Often themeasurements are carried out in back-
scattering geometry without requiring transmission of light through the
specimen. This feature is useful in particular for in-vivo diagnostic and
for examination of thick tissue specimens (e.g. surgical resections),
without requiring micro-sectioning. The use of visible or near-infrared
light for excitation also reduces the absorption effects of water, allowing
measurements of body ﬂuids or cells within water environments.
Similar to other optical techniques, Raman spectroscopy can
provide real-time (or near real-time) molecular information and high-
resolution imaging at relatively low cost compared to other well-
established medical imaging techniques (e.g. ultrasound, magnetic res-
onance imaging, etc.). This is an important feature as often the clinical
implementation and translation of technologies are limited by practical,
logistical and ﬁnancial factors.
One of the main draw-backs of Raman spectroscopy, that so far has
partly limited the translation into the clinic, is the relatively low efﬁ-
ciency of the inelastic light scattering compared to elastic scattering,
ﬂuorescence emission or absorption of infrared light. The low Raman
signals have often limited the speed of the technique. Compromises to
reduce acquisition times can decrease diagnosis accuracy when spectra
are acquired with insufﬁcient signal-to-noise ratios, or with spatial
under-sampling. Nevertheless, new strategies have been recently devel-
oped to address this limitation: imagingmodalities based on non-linear
Raman scattering, multimodal integration and selective-sampling
Raman microscopy, the use of nanomaterials and photonic structures
to enhance the Raman signals, ﬁbre-optics probes for hand-held
diagnostic devices and endoscopes, spatially-offset and needle-probes
for deep and subsurface diagnostics. These developments have made
important steps toward maximising the diagnostic accuracy and
speed, and often rely on cost-effective solutions that are likely to be
adopted into the healthcare services.This paper reviews the main Raman spectroscopy techniques used
for biomedical diagnostics and provides an overview of applications,
including bioﬂuids, cells and tissues. The article does not aim to be a
complete record of all papers in this research area, but instead focuses
on selected papers that emphasise recent advances or deﬁne new
trends in the ﬁeld. Section 2 describes the main Raman spectroscopy
techniques, including methods for spectral imaging of cells and tissue.
Section 3 presents diagnostics examples of tissue samples, in-vivo and
ex-vivo imaging, in-vivo diagnosis based on hand-held ﬁbre probes
and SORS. Section 4 focuses on Raman spectroscopy assays for bioﬂuid
analysis, including blood, saliva, urine and tear samples.
2. Raman spectroscopy techniques
2.1. Raman micro-spectroscopy
Theuse of excitation laserswithwavelengths in the visible and near-
infrared regions permits efﬁcient coupling of Raman spectrometers
with optical microscopes [1]. Such Raman micro-spectrometers allow
mapping of the molecular properties of the samples with diffraction-
limited spatial resolution (300–500 nm). The most common method
for obtaining Raman spectral images is by raster-scanning the sample
through the laser spot (or scanning the laser spot across the sample)
and then applying a uni- or multivariate spectral model to each
Raman spectrum. Raman spectral imaging based on line-mapping [2]
(i.e. laser beam expanded to form a line spot on the sample surface)
can considerably decrease the imaging time compared to single-point
raster-scanning, up to a factor equal to the number of simultaneously-
measured sampling points, provided the laser power used for single-
pointmapping canbemaintained over thewhole laser line. Recent stud-
ies have demonstrated that an increase of a factor of 10 can realistically
be achieved for imaging tissue samples, compared to point-by-point
scanning [3]. More recently, multifocal Raman micro-spectrometers
based on diffractive optical elements [4] or spatial light modulators [5]
have been proposed for simultaneous read-out of multiple Raman spec-
tra. Shuttering systems using different masks or arrays of optical ﬁbres
were used to couple the microscope to the Raman spectrometer by
matching the pattern of the laser beams on the sample to the ﬁbre/slit
pattern. If only uni-variate Raman models are used, the speed of
Raman spectral imaging can be signiﬁcantly increased by wide-ﬁeld
Raman microscopy: the laser is expanded to illuminate the entire area
of the sample and the scattered Raman light corresponded to selected
wavenumbers are imaged on a CCD [6]. This approach may be difﬁcult
in applications where variations in the baseline of Raman spectra may
often obscure the small differences in the Raman bands used for discrim-
ination in the diagnostic model.
2.2. Selective-sampling Raman micro-spectroscopy
In many medical applications, for example the assessment of resec-
tion margins during cancer surgery, it is desirable to obtain high-
spatial resolution Raman spectral images for large samples (e.g.
1–5 cm). In such cases, the techniques based on raster-scanning are
often not suitable because of the long data acquisition time required
for recording the datasets of Raman spectra. For example, achieving
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resolution of ~20 μm, requires typically acquisition times of one day
(~5 h per 1 mm2) [7–9]. In selective sampling, information regarding
the spatial features of the sample, either measured by an alternative op-
tical technique [7,10] or estimated in real-time from the Raman spectra
[11,12], can be used to reduce the number of Raman spectra by more
than two orders of magnitude.
The ﬁrst approach developed by Rowlands et al. [13] estimated the
main features of the sample in real-time; the next sampling point for
Raman spectroscopy is selected as the location with the maximum ab-
solute difference between two interpolating surfaces for the already
measured Raman spectra. In regions of the sample with few spatial
features, the two interpolants should converge on the same result. How-
ever, in the regions with a higher level of spectral variation, the differ-
ence between the two interpolants provides an indication of the
optimal point to measure next. In this way, the algorithm samples
regions of uncertainty with high resolution, at the expense of regions
containing relatively few spatial features. The feasibility of using this se-
lective samplingmethod for imaging cells and tissues has been demon-
strated [10–12]. A different approach for determining the optimal
positions of the sampling points for Raman spectroscopy is to use a
much faster alternative imaging technique that has high sensitivity to
the features of interest but not necessarly high speciﬁcity; these features
of interest are then used to generate and prioritise the sampling points
for Raman spectroscopy [7]. The key advantages of this approach are:
i) reduced number of Raman spectra, hence fast data acquisition and pro-
cessing and ii) the spatial-resolution is not compromised by the reduced
number of Raman spectra because resolution is determined by the alter-
native optical technique used to establish the spatial features of the sam-
ple (e.g. confocal ﬂuorescence microscopy [6]).2.3. Coherent anti-Stokes Raman spectroscopy (CARS) and stimulated
Raman spectroscopy (SRS)
Spontaneous Raman scattering, which relies on a single excitation
laser beam, is an incoherent phenomenon because the molecular vibra-
tions in a sample are not correlated. Coherent Raman spectroscopy tech-
niques rely on non-linear effects to increase the speed and spatial
resolution of Raman spectroscopy by inducing coherent molecular
vibrations in the sample. Coherent anti-Stokes Raman spectroscopy
(CARS) uses a “pump” laser (frequency νp) and a “Stokes” laser
(frequency νS) to drive coherent vibrations of themolecules at selected
frequencies (frequency νvib). Typically, one laser frequency is ﬁxed at νS
and the other is tuned to νp to excite the molecular vibrational mode of
interest at a frequency νvib= νp− νS. In this process, three photons are
absorbed, two “pump” photons and one “Stokes” photon, and the signal
corresponding to “anti-Stokes” photons of frequency νAS = 2νp− νS is
detected to create the CARS images. CARS has been mostly used to
image cells and tissues by exciting the CH stretching vibrations
(2600–3000 cm−1) in lipids and proteins [14]. Recently, broadband
CARS techniques, in which multiple Raman transitions are probed
simultaneously, have been extended in the ﬁngerprint region to allow
imaging of biological tissues with improved molecular contrast [15].
Stimulated Raman scattering (SRS) is based on only one “pump” and
one “Stokes” photons. When the difference between the frequencies of
the “pump” and “Stokes” photons match the frequency of a molecular
vibrational mode νvib = νp − νS, stimulated excitation of vibrational
transitions occurs. In this case the “Stokes” beam experiences stimulat-
ed Raman gain while the pump beam experiences stimulated Raman
loss. High-frequency modulation of either “Stokes” or “pump” beams
can be used to detect the small beam intensity changes and generate
high-speed images at selected vibrational frequencies. Compared to
CARS, SRS is free of non-resonant background and high-speed images
of cells and tissues have been reported [16]. Both CARS and SRS micros-
copy are based on non-linear optical effects, therefore the spatial-resolution of these techniques are superior to spontaneous Raman
micro-spectroscopy.
2.4. Surface enhanced Raman spectroscopy (SERS)
An alternative method to enhance the weak signals in spontaneous
Raman spectroscopy is to use metallic nanostructures capable to
provide surface enhanced Raman scattering [17]. When the molecules
of interest are adsorbed or located in the vicinity of such a metallic
nanostructure, enhancement of the Raman scattering occurs due to
the resonant interaction of light with the surface plasmons excited at
the surface of the structure (electromagnetic enhancement) [18,19].
This resonant interaction creates an enhanced electric ﬁeld (10–100×)
localised to a region of only few nanometres from the surface. This
increase in the localised electric ﬁeld subsequently can lead to a
~105–106 fold enhancement for the Raman bands formolecules located
in the vicinity of the surface. An additional enhancement, chemical en-
hancement, can also be observed for molecules adsorbed at the surface
of the nanostructure due to electronic interactions between the mole-
cule and surface. Physio- or chemisorption perturbs the polarisability
tensors of the molecules, leading to changes in the intensity of Raman
bands [20]. In addition, resonant Raman scattering effects can be ob-
served due to excitation into a charge-transfer transition [21]. Another
strategy in SERS diagnostics is the use of tailored nanoparticles as
markers conjugated with speciﬁc antibodies. The corresponding anti-
bodies are labelled by SERS-active nanoparticles, comprising of metallic
nanoparticles with chemisorbed Raman reporter molecules. The feasi-
bility of this approach for tissue diagnostics has been demonstrated
[22].
2.5. Spatially offset Raman spectroscopy (SORS) and transmission Raman
spectroscopy (TRS)
Traditional Raman spectroscopy, when illuminating and collecting
light from the same area, in tissues usually has a maximum penetration
depth of a few hundredmicrons, thus, restricting analysis to the surface
or near-surface area of samples. The development of spatially offset
Raman spectroscopy (SORS) has enabled spectral measurements from
volumes as deep as 10–20mm into the sample. SORS involves collecting
the scattered light away from the point of laser illumination [23,24].
With increasing spatial offset of the collection and the illumination
points, measurements deeper in tissue are possible. Clinical applications
of deep Raman techniques may include applications in urology, bone
and breast disease [25–27].
Transmission Raman spectroscopy (TRS) is an extreme form of
SORS, whereby the collection and illumination points are on opposite
sides of the sample [28]. This approach is ideally suited for bulk analysis
of opaque/turbidmaterials and has been shown to be feasible through a
many millimetres of tissues. Despite the sample being opaque, light
from the laser can pass through the sample via light scatteringprocesses
andmany of these photons contain Raman information, and thus trans-
mission Raman spectroscopy is feasible. Applications to breast cancer
diagnosis have been investigated [29].
The combination of the powerful techniques of SERS and SORS has
led to the development of the novel approach of surface enhanced
spatially offset Raman spectroscopy (SESORS). To date it has been dem-
onstrated that the presence and location of up to 4 labelled nanoparti-
cles can be measured through tissue thicknesses of between 20 and
50 mm [30,31]. Bisphosphonate-bone functionalization [32] and
glucose sensing [33] have also been demonstrated.
2.6. Fibre-optic Raman probes
Raman spectroscopy is suitable for use with ﬁbre-optic probes,
making it potentially ideal as a medical diagnostic tool for assessment
of hollow organs. Fibre-optic probes designed for in vivo use must
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of Raman signals and photoluminescence generated in the laser deliv-
ery ﬁbres themselves. For certain applications, all this must be achieved
with a probe of very small size to enable access to body cavities, and in a
sufﬁciently short time to allow accurate measurement from a moving
target organ [24–27]. Furthermore, spectral sampling volumes can be
critical for accurate identiﬁcation of early disease in certain conditions
such as dysplasia, when probing for early disease close to the surface
of an organ [26,27]. Further miniaturisation can allow measurement of
Raman signals through needles (see Fig. 1) and thus allow access to
solid organs such as lymph nodes, prostate and breast [34–38].
To avoid the intense background signal generated in the fused-silica
ﬁbres in the ﬁngerprint region (600–1800 cm−1), some ﬁbre-optic
Raman probes have been developed to work in the high-wavenumber
region (2400–3800 cm−1) [29]. These probes can use a single ﬁbre for
guiding laser light to the sample and for collecting the Raman scattered
light. This conﬁguration has been demonstrated to provide high-quality
high-wavenumber Raman spectra of tissue with almost no Raman
background signal from the ﬁbre [39]. An alternative method has been
explored for ﬁltering the elastically scattered laser line from the collec-
tionﬁbres and thusminimising the induction of background signal from
ﬁbres. This uses in-line ﬁbre Bragg gratings (FBG) to reject/reﬂect the
laser light in the collection path. A Raman probe was built consisting
of one excitation ﬁbre and six multicore single-mode ﬁbres (19 cores)
with inscribed FBGs as collection ﬁbres [40].
3. In-vivo and in-vitro Raman diagnostics based on tissue analysis
3.1. Brain cancer
Around 45% of brain tumours are gliomas, which are currently diag-
nosed by a combination of CT scanning, magnetic resonance imaging
and electroencephalogram, followed by surgical excision for deﬁnitive
identiﬁcation of pathology. Because often neoplastic tissue cannot be
distinguished from healthy tissue during the surgery, one of the key
challenges in brain tumour surgery is to delineate normal tissue from
tumour in order to avoid neurologic deﬁcit associated with damaging
functional cerebral structures. On the other hand, incomplete removal
of the tumour increases the risk of tumour recurrence.
Earlywork byKoljenovic et al. showed thatﬁbre-optic Ramanprobes
based on the high-wavenumber spectral region (2400–3800 cm−1) can
be used to characterise porcine brain tissue ex-vivo [41]. The measure-
ment of the high-wavenumber spectral region avoids the background
Raman scattering from silica ﬁbres while still providing high-chemical
speciﬁcity and diagnostic power [39,42]. The authors developed
multivariate classiﬁcation model (least-squares ﬁtting) that allowed dis-
crimination of brain structures based on the biochemical contrast.
The Raman spectra of grey matter was characterised by high intensity
bands associated with proteins, DNA, and phosphatidylcholine comparedFig. 1. Raman needle probe, constructed using one illumination and one collection ﬁbre,
with appropriate spectral ﬁltration included in the syringe body [28]. Reprinted with
permission from Springer.withwhitematter, while the spectra of whitematter was dominated by
spectral features corresponding to cholesterol, sphingomyelin, and
galactocerebroside.
The potential of using a ﬁbre-optic Raman probe for in-vivo diagno-
sis of brain tumours was investigated by Kirsch et al. [43]. Raman spec-
tral maps over areas 3.6 × 3.2 mm2 allowed label-free diagnosis of
induced metastatic brain tumours in mice with accuracy of ~250 μm.
[43]. Krafft et al. used Raman spectroscopy in the ﬁngerprint region
(600–1800 cm−1) to investigate primary brain cell density [44]. For
high-grade gliomas, the Raman spectra had higher contribution from
nuclei acid compared to normal tissue. The authors also demonstrated
the ability to create Raman spectral images by raster-scanning, which
were in good correlationwith the images obtained byH&E staining [45].
Spectral images of brain tissue with higher-spatial resolution have
been reported using coherent Raman micro-spectroscopy techniques.
CARS imaging tuned to probe C–Hmolecular vibrationswas used to an-
alyse human tumours (glioblastoma, brainmetastases ofmelanomaand
breast cancer) induced in an orthotopic mouse model [46]. As all brain
tumours have signiﬁcantly lower lipid content compared to the normal
parenchyma, CARS images can clearly delineate the tumour borders and
inﬁltrations. Ji et al. developed a technique based on SRS for real-time
imaging guidance for brain tumour surgery [47]. SRS images obtained
at 2930 and 2845 cm−1, bands corresponding to lipids and proteins,
allowed differentiation of tumour from nonneoplastic tissue in an
inﬁltrative human glioblastoma xenograft mouse model (correlation
between SRS and H&E images for glioma inﬁltration was k = 0.98).
The technique was also used in-vivo during surgery on mice to image
tumour margins that were undetectable under standard operative
conditions (Fig. 2).
Medyukhina et al. have reported new algorithms for automated
calculation of quantitative values (such as cell density, nucleus-to-
cytoplasm ratio, average nuclear size) that can be used for objective
diagnostic of brain tumours based on non-linear Raman microscopy
[48]. Using co-registered two-photon excited ﬂuorescence (TPEF) and
CARS images of human brain tumour samples, the grayscale informa-
tion was used to detect the location of the cell nuclei while the gradient
information allowed delineation of the nuclear and cellular boundaries.3.2. Breast cancer
Breast cancer is the second most common cancer and the most
common cause of death from cancer among women [50]. In Europe,
more than ~450,000 new patients are diagnosed each year. Treatment
depends on the type, stage and grade of the breast cancer [50]. Early
detection of tumours through X-ray mammography screening has led
to a signiﬁcant increase in survival rates, as well as more conservative
treatments and improved cosmetic outcomes. Nevertheless, mammog-
raphy has a high-rate of false-positives and further biopsy diagnosis by
histopathology is required (70–90% of biopsies are found to be for
benign lesion) [51]. Therefore, new alternative techniques for in-vivo
diagnosis are required.
Early work by Haka et al. showed that Raman spectroscopy can
discriminate between breast malignancies and healthy breast tissue
[52]. Kneipp et al. usedmultivariate spectral analysis to discriminate be-
tween normal duct epithelia and epithelium-derived breast tumours
[53].More recently, Kong et al. used Ramanmicro-spectroscopy to com-
pare spectra obtained from ductal carcinoma (DC), surrounding inﬂam-
matory stroma and tissue areas containing other components of healthy
breast tissue (lobules, ducts, stroma, fat) [10]. The authors showed that
the Raman spectra of DC have more intense spectral bands assigned to
nucleic acids (788 cm−1, 1098 cm−1) compared to other tissue struc-
tures. The Raman spectra of tumour-surrounding inﬂammatory stroma
had lower intensity bands corresponding to collagen and higher inten-
sity bands assigned to nucleic acids compared to the Raman spectra of
normal stroma.
Fig. 2. Using stimulated Raman spectroscopy for in-vivo imaging mouse brain during tumour excision [49]. (A) Tumour located beneath the cortical surface; (B) the tumour is detected
after removal of part of the cortex; (C) tumour was resected deep and the resection margins appear tumour-free. Reprinted with permission from Science.
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[54]. The main aim of the study was to measure the composition of
breast calciﬁcations and provide diagnosis for the lesions containing
them — calcium oxalate is found only in benign lesions and calcium
hydroxyapatite found in proliferative lesions, which include benign
and malignant lesions. These preliminary studies carried out on breast
phantoms showed the potential to identify calcium hydroxyapatite
and calcium oxalate monohydrate from depths of up to 2–3 cm
(Fig. 3). The approach of using in-vivo TRS to link the composition of
breast calciﬁcation with the pathology would improve the efﬁciency
of breast cancer screening and avoid unnecessary biopsies. A parallel
study on 235 calciﬁcations from 110 patients demonstrated the signiﬁ-
cant negative correlation between carbonate concentration and advanc-
ing malignant pathology grade [55]. TRS has been shown to provide a
prediction of carbonate concentration in calcium hydroxyapatite from
measuring the phosphate 960 cm−1 peak alone [56].
Raman spectroscopy has also been proposed for detection of tumour
margins during breast cancer surgery, both in-vivo and ex-vivo. A hand-
held Raman probe was developed for in-vivo collection of single-point
Raman spectra during surgery [57]. The authors measured 30 Raman
spectra from nine patients: 29 from margins subsequently found to be
negative on pathology examination (21 were composed of normal
breast tissue whereas 8 contained ﬁbrocystic change) and 1 spectrum
fromamargin subsequently found to be positive on pathology examina-
tion (high-grade ductal carcinoma in-situ). Although only one malig-
nant sample was included, this study showed the potential for in-vivo
detection of tumour margins during surgery. Alternatively, conﬁrmingnegative resection margins can be achieved by analysing the surface of
the resection specimen ex-vivo. To avoid sampling errors due to single
point measurements, CARS has been used to provide molecular images
of breast tissue and identify the tumour margins and differentiate its
subtypes [58]. The authors were able to image ex-vivo human normal
breast tissue, benign proliferative, as well as in-situ and invasive
carcinomas. By analysing the morphological features (geometry
and distribution of cancer cell nuclei) in the CARS images (typically
120 μm × 120 μm), cancerous lesions were separated from normal tis-
sue and benign proliferative lesion: 80% of intermediate-grade invasive
ductal carcinoma (IDC) and 85% of high-grade IDCwere correctly distin-
guished [58]. A recent study based on selective-sampling Raman
microscopy using integrated auto-ﬂuorescence imaging and Raman
spectroscopy demonstrated the feasibility to detect mammary carcino-
mas ex-vivo within time-scales compatible with intra-operative use for
breast conserving [10]. In this technique, Raman spectra in the ﬁnger-
print region (600–1800 cm−1) were collected at the locations indicated
by the auto-ﬂuorescence images. Objective diagnosis of mammary
ductal carcinoma was achieved with only 250–550 Raman spectra for
5 mm × 5 mm tissue specimens (equivalent to ~15 min) [10].
In addition to the assessment of resection margins, the feasibility of
using Raman spectroscopy for intra-operative assessment of sentinel
axillary lymph nodes during breast cancer surgery has also been ex-
plored [59]. Horsnell et al. demonstrated the ability to discriminate nor-
mal and metastatic lymph nodes using multivariate classiﬁcation
models, achieving 85–92% sensitivity and 88–100% speciﬁcity in a
leave-one-out cross-validation [60].
Dielectric filter
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Fig. 3. Experimental conﬁguration of TRS demonstration [44] using a pork tissue block to simulate human breast and known calciﬁcation standards inserted into the centre of the tissue.
830 nm laser illumination was used. Note the clear differences in spectra measured from type I and type II calciﬁcations. Reprinted with permission from Cancer Research.
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Lung cancer is the second most common cancer in humans and, de-
spite advances in surgical, radiotherapeutic, and chemotherapeutic
treatments, long-term survival rate remains low (5% at 10 years for
non-small cell lung cancers) [61]. One of the main reasons for the low
survival-rates is that ~75% of patients have late-stage disease, when ef-
fective treatment is unlikely to succeed. The feasibility of screening for
high-risk populations is currently debated in Europe and the USA [62].
One of the major challenges for the CT screening programmes is related
to the high-rate of false positives, which highlights the need for
improved diagnostic techniques.
An early study conducted by Huang et al. [63] used Raman spectros-
copy to distinguish tumour from normal bronchial tissue specimens,
squamous cell carcinoma and adenocarcinoma. The Raman spectra of
malignant tumour tissue was characterised by higher intensity bands
corresponding to nucleic acids, tryptophan and phenylalanine and
lower signals for phospholipids, proline and valine, compared to normal
tissue. The authors found that the ratio of the Raman band intensity at
1445 cm−1 and 1655 cm−1 had high discrimination power between
normal and tumour tissues.
Raman spectroscopy has also been used to predict the prognosis of
non-small cell lung cancer patients by analysing surgically resected
tissue sections [64]. Raman microscopy based on raster-scanning and
multivariate statistical analysis was able to predict early postoperative
cancer recurrence with a sensitivity of 73% and speciﬁcity of 74%. The
analysis of the Raman spectra indicated that high porphyrin levels in
the normal samples and intense bands corresponding to DNA in the
tumour samples allowed discrimination between normal and tumour
tissue. The use of CARS to provide differential diagnosis of lung-carcinoma (adenocarcinoma, small cell carcinoma and squamous cell
carcinoma) was also investigated [65]. CARS images corresponding to
the CH2 vibrationalmode (2845 cm−1)were analysed usingpattern rec-
ognition algorithms and indicated signiﬁcant morphological differences
between normal tissue and tumour regions: cancer regions showed
higher density of cells compared to normal regions, and the size and
conﬁguration of the cells corresponded with deﬁned parameters [66].
The feasibility of increasing the diagnosis speciﬁcity for pre-
neoplastic lesions in-vivo was investigated by integrating Raman spec-
troscopy measurements to a bronchoscope based on white light and
auto-ﬂuorescence [67]. White light and auto-ﬂuorescence images
allowed identiﬁcation of suspicious lesions, areas from which Raman
spectra were measured with acquisition times of 1 s. The authors
showed that sensitivity of 96% and a speciﬁcity of 91% for discrimination
of pre-neoplastic lesions (leave-one-out cross validations) by develop-
ing multivariate statistical models.
3.4. Skin cancer
Skin cancer is themost common type of cancer in humans. In the UK
and USAmore than 100,000 and 1,000,000 cases, respectively, are diag-
nosed annually [68,69]. Given the easy optical access to skin, numerous
studies have investigating the use of Raman spectroscopy for in-vivo
diagnosis of skin cancers. Preliminary work by Lieber et al. using a
ﬁbre-optic Raman probe indicated high-diagnosis accuracy for non-
melanoma skin cancers: 100% sensitivity and 91% speciﬁcity for
discriminating tumours from normal skin [70]. More recently, Lui et al.
developed a hand-help Raman probe that allowed real-time (less than
1 s) in-vivo diagnostic [71]. Using this probe in a study on more than
1000 cases of skin cancers and other skin diseases, the authors showed
Fig. 4. Diagnosis of basal cell carcinoma of the skin (BCC) by multimodal spectral imaging based on auto-ﬂuorescence imaging and Raman spectroscopy. Scale bar: 2 mm [7]. Reprinted
with permission from the National Academy of Sciences of the United Stated of America.
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benign lesions, melanomas from benign pigmented skin lesions,
and melanomas from seborrheic keratoses, with sensitivities be-
tween 95% and 99% [59]. Nevertheless, the speciﬁcity of these
models was low, ranging between 15% and 54%, when discriminating
malignant melanoma from non-melanoma pigmented lesions and
seborrheic keratosis [71].
For high-risk BCCs, Mohs micrographic surgery (MMS) is the best
treatment option. In this technique sequential layers of skin tissue are
excised and the entire resection margin is assessed intra-operatively
by frozen-section histopathology. This procedure ensures complete re-
moval of tumour cells, while sparing asmuch healthy tissue as possible.
The 5-year recurrence rate for BCC treated by MMS is 1.4–2.5%, signiﬁ-
cantly lower than 3.2–10% for standard excision [72]. Nevertheless,
the high costs associated with intra-operative assessment of tissue re-
sections by frozen section histopathology have limited the widespread
implementation of MMS. Early studies by Nijssen et al. showed that
BCC can bediscriminated fromnormal tissue based on a higher intensity
of Ramanbands associatedwith nucleic acids [73]. A two-step classiﬁca-
tion model achieving 100% sensitivity and 93% speciﬁcity (leave-one-
out cross-validation) was developed to diagnose BCC based on Raman
spectra obtained by raster-scanning over areas of 0.005–0.4 mm2 [73].
Larraona-Puy et al. reported a classiﬁcation model based on selected
Raman bands characteristic to nucleic acids and proteins that allows
discrimination of BCC from normal tissue with 90 ± 9% sensitivity and
85 ± 9% speciﬁcity [8]. This multivariate classiﬁcation model was then
applied to tissue sections from new patients and obtained objective di-
agnosis images that agreed with histopathology. To increase the speed
of diagnosis, a multimodal approach based on CARS, second-harmonic
generation (SHG) and two-photon excited ﬂuorescence (TPEF) has
been recently developed elsewhere [74]. The application of CARS/
TPEF/SHG multimodal microscopy allows for a characterisation of the
architecture and biochemical composition, i.e., the morphochemistry of
frozen section biopsy specimens. In doing so a rapid discrimination
between healthy and dysplastic/tumourous tissue comparable with the
gold-standard histopathology can be obtained [74,75]. Algorithms were
developed to facilitate handling and interpretation of the multimodalimages to create large spectral maps that provided tissue classiﬁcation
and objective tumour diagnosis [48,76].
In a different multimodal approach, auto-ﬂuorescence (AF) imaging
was used to determine the main spatial features of skin resections with
high spatial resolution, then this information was used in an automated
manner to select and prioritise the sampling points for Raman spectros-
copy. For skin samples of 4 mm × 4mm, the AF-Ramanmultimodal ap-
proach provided diagnosis similar to raster scanning Ramanmicroscopy
but with a dramatic increase in acquisition speed: AF-RS typically re-
quired ~100-fold fewer Raman spectra compared to raster scanning
[7]. Fig. 4 shows typical examples of using AF-Raman for detection of
BCC in skin resections obtained during Mohs surgery. Accurate assess-
ment of resection margins was obtained with only 500–1500 Raman
spectra for skin samples of 1 × 1 cm2 removed during Mohs surgery,
without requiring sectioning, staining or any other tissue preparation
stage [7].
3.5. Oesophagus
In response to the twin stimuli of the need for improved surveillance
and targeted endotherapies, a number of emerging technologies are
being developed with the aim of improving the identiﬁcation of
Barrett's oesophagus and associated neoplasia. The ability of Raman
spectroscopy to discriminate between 8 pathological groups from
normal squamous through to cancer has been demonstrated. A biopsy
targeting model, differentiating normal vs. Barrett's vs. dysplasia/
adenocarcinoma, achieved a high level of agreement with consensus
pathological opinion [77]. Much work in the oesophagus has been
aimed at the development of a ﬁbre-optic Raman probe for in vivo
use, designed to be compatible with medical endoscopes. Initial work
in rat models in-vitro showed potential for in vivo applications [78].
Safety and feasibility of using Raman probes in the oesophagus were
shown using an Enviva Visionex probe. 400 spectra in 20 patients
were measured using 5 second acquisition times, although discrimina-
tion of pathology was poor [79] due to large sampling depths. This
was followed upwith a custom-built probe whichwas used to discrim-
inate Barrett's, low-grade dysplasia (LGD) and high-grade dysplasia
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192 spectra from 65 patients with Barrett's oesophagus using 5 second
acquisition times [80].
In vivo diagnosis of oesophageal cancer with Raman ﬁbre-optic
probes has been reported with sensitivity 91% and speciﬁcity 94%,
although subtypes of cancer or degrees of dysplastic change were not
differentiated. This study measured 263 oesophageal Raman spectra
from 80 patients (33 with cancer) with relatively fast acquisition
times of 0.4–0.5 s [81,82]. Accurate recognition of pathology subtypes
using spectra acquired in 1 s using a Raman probe, giving sensitivities
and speciﬁcities for normal squamous of 87% and 96% respectively,
Barrett's/LGD 72% and 91%, HGD/ adenocarcinoma 86% and 88%. Using
a 2 group model with spectra acquired over 5 s the detection rate of
HGD/ adenocarcinoma remained 86%, but the speciﬁcity was greatly
improved at 98% [83].
Raman spectral mapping of oesophageal tissue micro-sections has
been used to characterise the biochemical changes underlying the spec-
tral differences. Pseudo-colour principal component score maps were
used identify altered cellular constituents associated with malignancy.
Dysplastic glandular tissue showed higher levels of DNA, actin and
oleic acid, whereas normal squamous tissue had a higher glycogen con-
tent [84]. Rapid mapping of tissue sections using Raman spectroscopy
has the potential to be used as an automated histopathology tool.
Hutchings et al. showed that mapping could be performed in clinically
applicable timescales e.g. 2 mm diameter sections over 30–90 min,
and that this was sufﬁcient to discriminate pathology [3,85].
3.6. Prostate cancer
Prostate cancer is one of themost cancer types inmen, accounting for
approximately a quarter of all new cancer cases. Crow et al. were the ﬁrst
to describe the use of Raman spectroscopy in prostatic disorders [86].
Raman spectra obtained from the prostate suggested that the variations
in the glycogen and nucleic acid content between benign prostatic hyper-
trophy (BPH) and adenocarcinoma [86]. As Raman spectroscopy exam-
ines tissue at the molecular level, it has the potential to provide
additional prognostic information in early prostate cancer. Raman spec-
troscopy can be used in determining the biochemical basis for the differ-
ent pathologies within the prostate gland [87]. Further, the authors
suggested that the potential in-vivo applications of the technique could
be for guiding prostate biopsy procedures and the intra-operative assess-
ment of tumour resectionmargins during radical prostatectomy. In vitro,
Raman spectroscopy can be used to accurately identify BPH and three dif-
ferent grades of prostatic adenocarcinoma. The prostate algorithm was
able to differentiate benign samples (benign prostatic hyperplasia and
prostatitis) from prostate cancer, with an overall accuracy of 86%. As
Raman probes are suitable for use during endoscopic, laparoscopic, or
open procedures, this work paves the way for in vivo studies [88].
Raman spectra were measured from two well-differentiated,
androgen-sensitive cell lines and two poorly differentiated, androgen-
insensitive cell lines to differentiate between carcinoma prostate cell
lines of varying degrees of biological aggressiveness. Crow et al. were
able to identify the individual cell lines with an overall sensitivity of
98% and a speciﬁcity of 99% and demonstrated promising results of
Raman spectroscopy in the diagnosis and grading of carcinoma of the
prostate [89]. Grubisha et al. demonstrated the low-level and simulta-
neous determination of many complexed forms of prostate speciﬁc
antigen (PSA) using surface-enhanced Raman scattering (SERS) [90].
A recent review summarises clinical applications of the various
Raman technologies available for prostate cancer diagnosis [91].
3.7. Colorectal cancer
Early identiﬁcation and eradication of tumours is critical for improv-
ing the treatment outcome for patients with colorectal cancer. Although
screening by colonoscopy has signiﬁcantly increased the survival ratesfor patients, this technique has low speciﬁcity for discrimination of
adenoma and early adenocarcinomas from benign hyperplastic polyps
in-vivo. Other reviews have detailed the application of optical tech-
niques to colon cancer [92,93]. Initial studies using near-infrared Raman
spectroscopy investigated in vitro differentiation of normal mucosa,
metaplastic and adenomatous polyps and adenocarcinomas, achieving
sensitivities and speciﬁcities greater than 90% when compared with
conventional histopathology [38,79]. In the ﬁrst in-vivo study using
‘Visionex’ Enviva ﬁbre-optic Raman probes, the probe passed down the
accessory channel of a conventional colonoscope showed the ability to
differentiate between normal colon and hyperplastic and adenomatous
polyps with a sensitivity of 100%, speciﬁcity of 89% and overall accuracy
of 95% with spectra measured from 19 regions of 9 polyps in 3 patients
[94]. Elsewhere, an in-house developed Raman probe for ex-vivo
measurements on 105 colon specimens from either biopsies or partial
colectomies (41 normal specimens, 18 hyperplastic polyps and46 adeno-
carcinomas) from 59 patients. Diagnostic accuracy was in excess of 98%.
This study did not include adenomas, which are an intermediate patho-
logical group in the stepwise progression fromnormal tissue to adenocar-
cinomas. With acquisition times of 5 s, the authors developed diagnostic
algorithms that identiﬁed normal tissuewith 98.8–99.8% sensitivity 100%
speciﬁcity, hyperplastic polypswith 100% sensitivity and 100% speciﬁcity,
and cancerous tissue with 100% sensitivity and 98.1–99.7% speciﬁcity
[95].
A confocal endoscopic two-ﬁbre-optic probe [35] was utilised on ex-
vivo colonic tissues to evaluate its potential in vivo performance. Biop-
sies were collected and snap frozen, then measured with the probe
applied to the epithelial surface once defrosted. A miniature Raman-
endoscope system was used to measure spectra sequentially over a
period of several weeks to monitor tumour progression in 4 mice with
recognisable tumour lesions. Molecular changes in the tumour as it
progressed, such as altered collagen type I and lipid content were
measured and they were able to classify 86.8% of samples correctly as
tumour versus normal tissue, when compared to histopathology [96].
Recent work by Short et al. has examined the possible use of high
frequency Raman spectroscopy in the colon, measuring wavenumbers
in the range 2050 to 3100 cm−1 [97]. Although discriminatory peaks
were mostly detected at lower wavenumbers, measuring in this higher
range reduces the effects of tissue auto-ﬂuorescence and emissions in
the ﬁbre-optic probe itself. This means that cheaper probes can be pro-
duced without the need to ﬁlter the light within the probe. This small
study in ex vivo fresh tissue samples has shown that discrimination of
pathology subtypes is possible using these higher wavenumbers with
1 second acquisition times.
Raman spectroscopy has also been investigated as a potential
adjunct to histopathology, with the ultimate aim of either automated
sample analysis, or digital staining of a tissue section to assist patholo-
gist analysis. Rapid Raman mapping of snap-frozen tissue sections
used in conjunction with chemometric analytical techniques to inter-
pret spectral information, and demonstrated the ability to identify
many subtle histological features of colonic polyps. This technique
thus has the potential to reveal more biochemical information about a
tissue sample than standard chemical staining [98].
3.8. Bone disease
Many bone diseases arise because of subtle changes in the bone
protein chemistry but these are invisible to conventional techniques
like X-rays. Raman spectroscopy is potentially able to detect these
subtle molecular changes and its potential to enhance the diagnosis of
osteoarthritis (OA), brittle bone disease and fragility fractures has
been investigated. Frequency shifts serve as an important source of
contrast in assessing tissue composition such as carbonate substitutions
for phosphate positions in bone. The extracellular matrix also provides
another source of contrast to bone tissue composition. The extracellular
matrix contains many protein-rich vibrational modes, corresponding
Fig. 5. Four human tear samples drop dried on calcium ﬂuoride substrates andmeasuredwith 830 nmRamanmicroscopy. Top rowwhite light images, subsequent rows are PC scoremaps
and associated loadings (far right). All images are displayed on the same scale [106]. Reprinted with permission from Science Driect.
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Early studies compared the Raman spectral features of bone with
those of their major components, such as hydroxy and carbonated
apatite [99]. Raman spectroscopy has been used to evaluate alterations
to bone composition associated with ageing, disease, or injury to aid in
the diagnosis and prediction of fragility fractures [100]. OA is a common
debilitating disease that results in degeneration of cartilage and bone in
the synovial joints. Raman spectroscopy has shown that subtle changes
in the molecular structure of the subchondral bone matrix, or inherent
differences, exist in both the medial and lateral (beneath intact
cartilage) compartments of OA knees [101].
SORS enables the chemistry of bone tissue to be safely determined
severalmillimetres beneath the skin [102]. In-vivo SORSmeasurements
have been carried out investigating the potential for the detection of OA
[103]. Improvements in the quality of in vivo Raman spectra can be
obtained using the inverse SORS approach [26], as greater laser powers
can be applied for the same total laser intensity.4. Bioﬂuid diagnostic assays based on Raman spectroscopy
The analysis of bioﬂuids, such as blood and urine, can enable power-
ful minimally invasive diagnostics for many diseases [104]. Bioﬂuid
assays have several key advantages (accessibility, require less invasive
procedure, allow repeated sampling) and bioﬂuid diagnostic can be
implemented in a variety of healthcare scenarios, from being part of
routine health checks to intra-operative monitoring of blood or thera-
peutic agents.
Bodilyﬂuids can contain numerous biomolecules of diagnostic inter-
est, although not always of sufﬁcient concentration to be measured in
solution with Raman spectroscopy. One highly affective approach to
pre-concentrate the proteins found in the ﬂuids is drop coated deposi-
tion Raman spectroscopy (DCDRS) (Fig. 5). This has been shown to
provide an accurate measure of the concentration of protein mixtures
in solutions even when pre-concentrated [105]. The use of DCDRS has
been demonstrated in human tears indicating promise for measure-
ment of both local and systemic disease biomarkers [106,107].
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For diabetes patients, the blood glucose levelsmust bemonitored on
a regular basis, in some cases as often as four or ﬁve times a day. Never-
theless, the current devices used for measuring blood glucose level rely
on invasive procedures to produce a blood sample for analysis (e.g.
requiring pricking), which are painful and inconvenient for patients.
Raman spectroscopy has been used to measure the concentrations
of chemicals in blood serum(glucose, urea, proteins, cholesterol, triglyc-
erides, etc.), with results in good correlationwith reference values [108,
109]. Studies carried out on mouse blood samples showed that the
Raman band characteristic to glucose at 1125 cm−1 can be used tomea-
sure the concentration of glucose in the blood [109]. In-vivo measure-
ments performed transcutaneously (blood vessel in the mouse ear)
showed a linear correlation coefﬁcient of 0.91 between the glucose con-
centration recorded by Raman spectroscopy and reference values obtain-
ed by a blood glucosemetre. To increase the sensitivity required for rapid
glucose detection at the physiological concentrations' clinically relevant
range (0.56–25 mM), enhancement of the Raman signals by SERS has
been proposed [110]. SERS substrates based on functionalised silver coat-
ed self-assembled polystyrene nanospheres were used to measure in-
vitro glucose levels within the physiological range with a root mean
squared error of prediction of 4.62 mM [111]. Similar SERS substrates
were implanted in mice and the feasibility of in-vivo monitoring glucose
levels by transcutaneous SESORS measurements was demonstrated
[112].
A recent study employed Raman spectroscopy for diagnostic of type
II diabetes by detecting molecular changes in the membranes of eryth-
rocytes [113]. The membrane of red blood cells in patients with type II
diabetes is continuously exposed to high blood glucose levels, leading
to damage in structural components. Correlation between membrane
damage and glucose levels has been established by high-performance
liquid chromatography and thin-layer chromatography, but these
techniques require laborious procedures [114]. Raman spectroscopy
measurements in the high-wavenumber region showed that lipid
damages (decreased liquidity, altered phospholipid organisation) in
diabetic erythrocytes and multivariate statistical method achieved a di-
agnostic accuracy of 98.8% for differentiating diabetic versus normal
erythrocytes.
4.2. Cancer diagnostics
Detection of genetic and epigenetic materials originating from
tumour or circulating tumour cells in body ﬂuids represents an attrac-
tive alternative for faster and non-invasive detection of early cancers.
The feasibility of analysing urine samples by Raman spectroscopy
aimed at detection of prostate cancer cells was ﬁrst investigated by
Harvey et al. [115]. Integrated Raman microscopy and optical tweezers
was used to discriminate between malignant cells and bladder cells,
given the likelihood that both cell typeswill be present in urine samples.
The Raman spectra of the two cell types suggested a higher concentra-
tion of nucleic acids and proteins in the bladder cells compared to
the prostate cancer cells. Further work included androgen sensitive
CaP cell-line LNCaP, primary benign prostate hyperplasia cells and
primary urethral cells [116]. Multivariate classiﬁcation models based
on principal component-linear discriminate analysis indicated sensitiv-
ities and speciﬁcities of N93% and 98% respectively, using a validation
test based on blind comparison.
A proof-of-concept studywas reported by Taleb et al. [117] that used
Raman spectroscopy to analyse blood serum to discriminate cirrhotic
patients with and without hepatocellular carcinoma. Hepatocellular
carcinoma represents ~90% of primary liver cancers and is the third
most common cancer deathworldwide. Rapid and easy-to-use diagnos-
tic tools are required to allow detection of tumours at early stages when
patients are eligible for curative treatments. Multivariate spectral
analysis models were developed achieving an overall rate of accuracyof ~86–91%. Similar proof-of-principle studies based on blood serum
analysis by Raman spectroscopy have also been carried out for early
diagnostic of breast [118] and head-and-neck cancers [119].
Raman spectroscopy has been extensively used for analysis of white
blood cells as a potential diagnostic tool for lymphomas and leukaemia.
Early work by Chan et al. showed that single-cell Raman micro-
spectroscopywas able to discriminate between normal human lympho-
cytes and transformed Jurkat and Raji lymphocyte cell lines based on
highly reproducible biomolecular ﬁngerprints [120]. The neoplastic
cells were found to have lower DNA bands (785 cm−1, 1098 cm−1)
but stronger band characteristic to proteins (1126 cm−1, 1447 cm−1)
compared to normal lymphocytes. Multivariate statistical models
based on Raman spectra achieved a sensitivity of 98.3% for cancer detec-
tion, with 97.2% of the cells being correctly classiﬁed as belonging to the
normal or transformed type. The same research group found similar
high diagnostic accuracy for normal T and B lymphocytes from healthy
individuals and cells from leukaemia patients, based on Raman spectra
of individual cells [121].
Apart from confocal Raman microscopy, SERS has also been
proposed for phenotypic identiﬁcation of white blood cells aimed at
developing diagnostic tools for haematological malignancies [122].
Antibody-targeted, PEG-coated gold nanoparticles were used simulta-
neously to label three cell surface markers of interest on malignant B
cells from the LY10 lymphoma cell line. The authors demonstrated the
high speciﬁcity of these SERS particles on primary chronic lymphocytic
leukaemia and LY10 cells.
Non-invasive prostate cancer screening methods using serum
surface-enhanced Raman scattering (SERS) have been carried out
using serum samples from 93 prostate cancer patients and 68 healthy
volunteers by silver nanoparticles. Three types of kernel functions in-
cluding linear, polynomial, and Gaussian radial basis function (RBF)
were employed to build support vector machine (SVM) diagnostic
models for classifying measured SERS spectra. The study showed that
for the RBF kernel SVMdiagnosticmodel achieved a diagnostic accuracy
of 98.1%, demonstrating that label-free serumSERS analysis technique is
a promising tool for non-invasive prostate cancer screening [123].
The feasibility of detecting circulating tumour cells in the blood by
Raman spectroscopy has been recently investigated using integrated
Raman spectroscopy and optical tweezers based on microﬂuidic chips.
These integrated instruments allowedmeasurements of Raman spectra
of individual blood cells and were able to detect spectral features char-
acteristic to tumour cells [124,125]. The performance of this systemwas
tested for a tumour cell model that consisted of leucocytes extracted
from blood, breast cancer cells BT-20 and MCF-7 and leukaemia cells
OCI-AML3. A multivariate spectral model was developed that allowed
classiﬁcation of the cells with sensitivities between 97 and 100% (deter-
mined by iterated 10-fold cross-validation) [124].
4.3. Asthma
Assignment of asthma patients to a correct category (mild, moder-
ate, severe or very severe) is important to allow the selection of an
optimal treatment. An assay based on Raman spectroscopy analysis of
blood serumwasproposed for diagnosing asthma andmonitoring treat-
ment response [126]. The assay was carried out on serum samples from
44 asthma patients of different grades (mild, moderate, treated severe
and untreated severe) and from 15 reference subjects. The results
showed that changes in protein structure and increase in Raman
bands characteristic to DNA and glycosaminoglycans were linked with
increase in asthma severity.
4.4. Inﬂammatory response
Raman spectroscopy was proposed to measure and quantify the
concentration of C-reactive protein (CRP) in blood plasma [127]. CRP
is a protein that can be used as a sensitive biomarker of inﬂammation
Fig. 6. Principal component analysis of Raman spectra measured for blood plasma from
Plasmodium infected mice. Samples are as follows: day 0 (red), day 1 (dark blue), day 2
(purple), day 3 (light blue), day 4 (orange) and day 7 (green). Mice A are shown as trian-
gles, mice B as squares andmice C as circles [134]. Reprintwith permission from the Royal
Society of Chemistry.
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viral infections. The typical concentration of CRP in humans is less than
10 mg/l, and can increase 2–3 orders of magnitude during inﬂammation.
The concentration of CRP is typically measured using immunoassays that
rely on laborious, expensive and time-consuming procedures. Berholt
et al. showed that a multivariate model based on partial least square
analysis (samples obtained from 40 patients) allowed quantiﬁcation of
CRP in blood serum with a root mean square error of cross-validation of
10.8 mg/l [127].
Raman spectroscopy was used to establish reliable biomarkers that
can be used to distinguish between non-infectious systemic inﬂamma-
tory response syndrome (SIRS) and sepsis [128]. The study was based
on Raman spectral measurements of blood samples obtained from 31
patients with sepsis and 39 patients classiﬁed with SIRS without
infection. A multivariate analysis model was developed that achieved
a prediction accuracy of 80% on an independent dataset.
4.5. Coagulant and anti-coagulant factors in human blood
Multivariate analysis based on partial least square regressions was
also used to measure the concentration of ﬁbrinogen concentration in
blood plasma [129]. Fibrinogen is a glycoprotein present in the human
blood that helps coagulation (normal level of ﬁbrinogen in the blood
is 1.5–3 g/l). The activation of ﬁbrinogen is involved in the pathogenesis
of inﬂammation, tumour growth and various diseases (concentrations
4–8 g/l). This preliminary study carried out on blood samples from 34
patients achieved a root mean square error of prediction of 0.72 ±
0.05 g/l. While the accuracy of Raman spectroscopy was lower than
the gold­standard assay (Clauss ﬁbrinogen assay for measuring throm-
bin clotting time), Raman spectroscopy is an attractive technique as it
can provide rapid and reagent-free quantitative results.
The use of Raman spectroscopy for monitoring the amount of
heparin in patients' blood during surgery has also been investigated
[130]. Calibration models based on partial least squares were able to
detect low concentrations of heparin in serum (~8 USP/ml) with a
root mean square error of prediction ~4 USP/ml.
4.6. Malaria
Malaria is one of themost deadly diseases of humans, responsible for
more than 1 million deaths in 2010 [131]. Early diagnosis of malaria is
important for decreasing mortality rates and reducing the overuse of
antimalarial drugs.
Raman spectroscopy has been extensively used for studying red
blood cells, including comparison between healthy erythrocytes and
erythrocytes infected with the malaria parasite Plasmodium falciparum
[132,133]. Given the strong signals due to the resonant Raman scatter-
ing, the spatial distribution of haemoglobin and hemozoinwas analysed
within individual blood cells.
In addition to analysing the red blood cells, recent studies have
focused on the analysis of blood plasma, as potentially a more efﬁcient
diagnostic method compared to blood smears. In malaria infected pa-
tients, rupture of erythrocytes releases hemozoin, heme and parasites
into the blood stream, which can be detected by Raman spectroscopy
analysis of plasma or serum in a more efﬁcient way than current tests
based on microscopic evaluation of blood smears. The feasibility of
this approach has been investigated by Hobro et al. [134]. Raman spec-
troscopywas used tomonitor the changes in plasmaduring Plasmodium
infection inmice, followingmalaria disease progression over the course
of 7 days (Fig. 6). The Raman bands corresponding to haemoglobin and
hemozoin indicated changes in the very early stages of infection, as
early as one day after Plasmodium infection. On the other hand, changes
in membranes of erythrocyte were detected only around day 4, indicat-
ing that plasma-based Raman assay may be more advantageous for
detection of malaria.5. Conclusions
The broad range of techniques and applications presented in this
article demonstrate the potential of Raman spectroscopy for medical
diagnostics, as well as the high interest in this technique. Raman spec-
troscopy can achieve high diagnosis accuracy, and results in many
applications that have been conﬁrmed across numerous different labora-
tories. Compared to other diagnostics assays, Raman spectroscopy can be
non-invasive, fast, and can achieve high chemical speciﬁcity based entire-
ly on intrinsic molecular contrast in biological samples. In addition, most
Raman spectroscopy techniques rely on established optical technologies
and offer cost-effective approaches when compared to conventional
medical imaging techniques, such as MRI, CT or ultrasound.
One of the most important features of Raman spectroscopy is the
ability to provide quantitative molecular information that can be trans-
lated into an objective diagnosis. Many optical imaging and microscopy
techniques used in medical diagnostics (including the gold standard
histopathology) aim to identify diseased cells based on their distribu-
tion, morphology, or interaction with speciﬁc stains or antibodies.
However, such techniques provide images that require subjective inter-
pretation, thus are prone to high inter-observer variability. Raman
132 K. Kong et al. / Advanced Drug Delivery Reviews 89 (2015) 121–134spectroscopy can measure both morphological and chemical informa-
tion in samples andmultivariate classiﬁcationmodels can be developed
to provide objective diagnosis of independent tissue samples obtained
from new patients.
The relatively low speed of Raman spectroscopy has been a main
weakness for clinical translation. However, recent advances in multi-
modal imaging and non-linear microscopy have demonstrated the abil-
ity to obtain high-contrast molecular images and provide objective
diagnosis for samples with clinically relevant dimensions and at speeds
compatible with clinical use. Important progress has also been reported
in sub-surface deep Raman spectroscopy, and innovative solutions and
optimised designs for ﬁbre-optic and needle Raman probes have been
reported for in-vivo diagnostic. The key challenge now is the clinical
translation and adoption of Raman technologies in the healthcare
service. These technologies must show improved clinical outcome
based on randomised clinical trials and need to demonstrate cost-
effectiveness compared to current practice.
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